Compare GSK Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs AJANTA PHARMA - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA AJANTA PHARMA GSK PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 51.3 23.5 218.5% View Chart
P/BV x 10.8 4.1 260.8% View Chart
Dividend Yield % 1.5 0.9 172.2%  

Financials

 GSK PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
AJANTA PHARMA
Mar-19
GSK PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,5951,422 252.8%   
Low Rs1,253898 139.6%   
Sales per share (Unadj.) Rs184.7233.5 79.1%  
Earnings per share (Unadj.) Rs26.344.0 59.8%  
Cash flow per share (Unadj.) Rs29.252.2 55.9%  
Dividends per share (Unadj.) Rs20.009.00 222.2%  
Dividend yield (eoy) %0.80.8 106.3%  
Book value per share (Unadj.) Rs126.3255.1 49.5%  
Shares outstanding (eoy) m169.4088.02 192.5%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x13.15.0 264.3%   
Avg P/E ratio x92.226.4 349.5%  
P/CF ratio (eoy) x83.122.2 373.8%  
Price / Book Value ratio x19.24.5 422.1%  
Dividend payout %76.120.5 371.6%   
Avg Mkt Cap Rs m410,626102,081 402.3%   
No. of employees `0005.06.8 72.9%   
Total wages/salary Rs m5,3724,307 124.7%   
Avg. sales/employee Rs Th6,306.73,022.6 208.7%   
Avg. wages/employee Rs Th1,083.1633.4 171.0%   
Avg. net profit/employee Rs Th898.0569.1 157.8%   
INCOME DATA
Net Sales Rs m31,28120,554 152.2%  
Other income Rs m1,023211 485.4%   
Total revenues Rs m32,30420,765 155.6%   
Gross profit Rs m6,0095,664 106.1%  
Depreciation Rs m486721 67.4%   
Interest Rs m612 51.7%   
Profit before tax Rs m6,5405,143 127.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,3731,273 186.4%   
Profit after tax Rs m4,4543,870 115.1%  
Gross profit margin %19.227.6 69.7%  
Effective tax rate %36.324.8 146.6%   
Net profit margin %14.218.8 75.6%  
BALANCE SHEET DATA
Current assets Rs m20,06111,812 169.8%   
Current liabilities Rs m14,5433,776 385.1%   
Net working cap to sales %17.639.1 45.1%  
Current ratio x1.43.1 44.1%  
Inventory Days Days5777 73.4%  
Debtors Days Days1482 17.2%  
Net fixed assets Rs m14,34314,398 99.6%   
Share capital Rs m1,694175 965.8%   
"Free" reserves Rs m19,70422,277 88.5%   
Net worth Rs m21,39822,452 95.3%   
Long term debt Rs m27 30.3%   
Total assets Rs m39,11326,962 145.1%  
Interest coverage x1,091.0444.3 245.5%   
Debt to equity ratio x00 31.8%  
Sales to assets ratio x0.80.8 104.9%   
Return on assets %11.414.4 79.2%  
Return on equity %20.817.2 120.8%  
Return on capital %31.923.0 139.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53410,682 5.0%   
Fx outflow Rs m7,0912,102 337.4%   
Net fx Rs m-6,5578,580 -76.4%   
CASH FLOW
From Operations Rs m3,9943,748 106.6%  
From Investments Rs m-1,433-2,228 64.3%  
From Financial Activity Rs m-3,584-1,475 243.0%  
Net Cashflow Rs m-1,02345 -2,263.7%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 1.6 658.1%  
FIIs % 23.8 7.6 313.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.0 90.6%  
Shareholders   102,036 20,968 486.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  PFIZER  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strengthening Rupee, Inflation & Factory Output Data, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets witnessed most of the buying interest during closing hours and ended on a strong note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 13, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS